Find

Search Newsmax Health Search Newsmax Search Web
Newsletters Video Shop Contact Us Archives
 
Newsmax Newsmax Moneynews Newsmax.TV
 
 
Health Stories  

Party Drug Ecstasy Could Treat Cancer

Friday, August 19, 2011 2:00 PM

Print this Page  

Forward Page  Forward Page

Email Us  Email Us

Researchers in Britain revealed Friday they are exploring whether the nightclubbers' drug ecstasy could be effective in treating blood cancers.

Scientists at the University of Birmingham in central England said modified forms of the drug boosted its ability to destroy cancerous cells by 100 times.

Six years ago, researchers found that cancers affecting white blood cells appeared to respond to certain "psychotropic" drugs.

These included weight loss pills, Prozac-type antidepressants, and amphetamine derivatives such as MDMA — commonly known as ecstasy.

The Birmingham scientists said their discoveries since then could lead to MDMA derivatives being used in patient trials.

The derivatives could be effective in treating blood cancers such as leukaemia, lymphoma, and myeloma.

"This is an exciting next step toward using a modified form of MDMA to help people suffering from blood cancer," said Professor John Gordon, from the university's School of Immunology and Infection.

"While we would not wish to give people false hope, the results of this research hold the potential for improvements in treatments in years to come."

The team found that the dose of MDMA required to treat a tumor would prove fatal, so they set about isolating the drug's cancer-killing properties.

They are now looking at ways to get MDMA molecules to penetrate cancer cell walls more easily.

"The prospect of being able to target blood cancer with a drug derived from ecstasy is a genuinely exciting proposition," said Dr. David Grant, scientific director of the Leukemia and Lymphoma Research charity, which partially funded the study.

"Many types of lymphoma remain hard to treat, and non-toxic drugs which are both effective and have few side effects are desperately needed."

The findings were published in the bi-monthly journal Investigational New Drugs.

Copyright AFP

 

 

   
   
   
       Privacy Policy  |  Terms & conditions  |  Contact Us

PLEASE NOTE: All information presented in Newsmaxhealth.com and Newsmax.com is for informational purposes only. It is not specific medical advice for any individual. All answers to reader questions are provided for informational purposes only. All information presented on our websites should not be construed as medical consultation or instruction. You should take no action solely on the basis of this publication’s contents. Readers are advised to consult a health professional about any issue regarding their health and well-being. While the information found on our websites is believed to be sensible and accurate based on the author’s best judgment, readers who fail to seek counsel from appropriate health professionals assume risk of any potential ill effects. The opinions expressed in Newsmaxhealth.com and Newsmax.com do not necessarily reflect those of Newsmax Media. Please note that this advice is generic and not specific to any individual. You should consult with your doctor before undertaking any medical or nutritional course of action